获1.73亿美元融资,Marrow Therapeutics瞄准镰状细胞病
STAT+: With $173 million, new startup takes aim at sickle cell
Marrow Therapeutics宣布成立并已筹集1.73亿美元A轮及B轮融资,投资方包括Scion Life Sciences、venBio和OrbiMed等。创始人Romesh Subramanian表示,该公司正开发一种用于治疗镰状细胞病的注射疗法,预期疗效与基因治疗相当但避免后者的诸多劣势,目前需进一步验证。
Marrow Therapeutics is trying to build an injection as effective as gene therapy
![]()
By Jason Mast
Nov. 17, 2026
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks.
Biotech entrepreneur Romesh Subramanian thinks he might have one. On Tuesday, he announced the founding of new startup Marrow Therapeutics to pursue it, with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed, and others.
“We expect it to be as good as [gene therapy] in patients,” Subramanian said, “but to be proven for sure.”
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
来源:STAT 主站 · statnews.com